山河药辅(300452) - 2021 Q1 - 季度财报

Financial Performance - Revenue for Q1 2021 reached ¥172,457,902.67, an increase of 37.80% compared to ¥125,148,306.34 in the same period last year[8] - Net profit attributable to shareholders was ¥31,114,589.36, up 30.46% from ¥23,850,090.72 year-on-year[8] - Basic earnings per share increased to ¥0.17, representing a growth of 30.77% compared to ¥0.13 in the previous year[8] - Operating revenue for the reporting period was RMB 172.46 million, a year-on-year increase of 37.80%, mainly driven by higher sales[22] - Net profit attributable to shareholders of the parent company was RMB 31.11 million, reflecting a year-on-year increase of 30.46% due to increased sales revenue[23] - The net profit after deducting non-recurring gains and losses was CNY 28.08 million, reflecting a 29.92% increase year-on-year[25] - The total comprehensive income for the first quarter was CNY 31,106,025, an increase from CNY 23,061,980 in the same period last year, representing a growth of approximately 35.5%[54] Cash Flow - Net cash flow from operating activities improved significantly to ¥3,109,006.22, a turnaround from a negative cash flow of -¥6,381,400.17 in the same period last year, marking a 148.72% increase[8] - Cash inflow from operating activities totaled CNY 126,903,305, up from CNY 97,995,359, marking an increase of about 29.5% year-over-year[57] - The company reported cash outflow from operating activities of CNY 123,794,299, compared to CNY 104,376,759 in the previous year, reflecting an increase of approximately 18.6%[57] - The net cash flow from investment activities was CNY 12,200,610, a rise from CNY 3,925,110, indicating a growth of about 211.5% year-over-year[58] - The cash and cash equivalents at the end of the period amounted to CNY 110,562,309, compared to CNY 90,597,448 at the end of the previous year, representing an increase of approximately 22%[58] Assets and Liabilities - Total assets at the end of the reporting period were ¥945,213,083.54, reflecting a 4.92% increase from ¥900,871,586.44 at the end of the previous year[8] - Total liabilities increased to CNY 258,050,426.59 from CNY 245,696,995.30, which is an increase of approximately 5.5%[41] - Total liabilities rose to ¥204,871,933.51 from ¥197,131,607.14, reflecting an increase in financial obligations[48] - The total equity attributable to shareholders rose to CNY 617,599,401.85 from CNY 585,208,911.21, indicating an increase of about 5.5%[42] Shareholder Information - The total number of shareholders at the end of the reporting period was 12,548, indicating a stable shareholder base[12] - The top shareholder, Yin Zhenglong, holds 26.88% of the shares, with a total of 48,505,734 shares[12] Research and Development - Research and development expenses amounted to RMB 5.98 million, a year-on-year increase of 49.25%, indicating increased investment in R&D[22] - Research and development expenses for the quarter were ¥5,977,315.53, compared to ¥4,004,768.03, highlighting a focus on innovation[48] Market and Operational Risks - The company faces risks from fluctuations in raw material prices, which could impact profit margins[26] - The company plans to enhance product quality and service levels to mitigate the impact of rising raw material costs[27] - The international market expansion is a strategic focus, with potential risks related to legal and regulatory understanding in foreign markets[26] - The company has established an international trade department to address potential political and legal risks in international operations[28] - The company emphasizes continuous R&D investment and innovation to maintain its competitive edge amid increasing market competition[28] Other Financial Metrics - Financial expenses increased by 153.38% to RMB 0.0472 million, primarily due to higher borrowing costs[22] - The company reported a significant increase in other non-current assets, which reached RMB 10.13 million, up 573.06% compared to the beginning of the period[20] - Deferred income increased to ¥29,823,764.98 from ¥22,965,126.04, indicating growth in future revenue recognition[48]